Gut peptide hormones: Importance for food intake

Scandinavian Journal of Gastroenterology

Volumn 40, Issue 3, 2005, Pages 250-258

  Näslund, Erik ^a   Schmidt, Peter T ^b   Hellström, Per M ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 2; OREXIN; OXYNTOMODULIN; PEPTIDE HORMONE; PEPTIDE YY;

APPETITE; ARCUATE NUCLEUS; CLINICAL TRIAL; ENERGY BALANCE; ENERGY EXPENDITURE; FOOD INTAKE; HORMONE ACTION; HUMAN; HYPOTHALAMUS; INSULIN RESISTANCE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SATIETY; SIGNAL TRANSDUCTION; SOLITARY TRACT NUCLEUS;

ANIMALS; APPETITE; EATING; GASTROINTESTINAL HORMONES; HUMANS; NERVE NET; NEUROSECRETORY SYSTEMS; SIGNAL TRANSDUCTION;

EID: 16444377963     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520410010634     Document Type: Review

References (113)

1. Hetherington AW, Ransom SW. Hypothalamic lesions and adiposity in the rat. Anat Rec 1940;78:149-72.
2. Anand BK, Brobeck JR. Hypothalamic control of food intake in rats and cats. Yale J Biol Med 1951;24:123-40.
3. Blevins JE, Schwartz MW, Baskin DG. Peptide signals regulating food intake and energy homeostasis. Can J Physiol Pharmacol 2002;80:396-406.
4. MacDougald OA, Mandrup S. Adipogenesis: forces that tip the scales. Trends Endocrinol Metab 2002;13:5-11.
5. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004;30:13-9.
6. Grill HJ, Norgren R. Chronically decerebrate rats demonstrate satiation but not bait-shyness. Science 1978;201:267-9.
7. Raybould HE. Does your gut taste? Sensory transduction in the gastrointestinal tract. News Physiol Sci 1998;13:275-80.
8. Bray GA. Afferent signals regulating food intake. Proc Nutr Soc 2000;59:373-84.
9. Rindi G, Necchi V, Savio A, Torsello A, Zoli M, Locatelli V, et al. Characterisation of gastric ghrelin cells in man and other mammals: Studies in adult and fetal tissues. Histochem Cell Biol 2002;117:511-9.
10. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:1714-9.
11. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yosimoto A, Harada M, et al. Ghrelin strongly stimulates growth hormone (GH) release in hummans. J Clin Endocrinol metab 2000;85:4908-11.
12. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-60.
13. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000;407:908-13.
14. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A role for ghrelin in the central regulation of feeding. Nature 2001;409:194-8.
15. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 2001;50:2438-43.
16. Riediger T, Traebert M, Schmid HA, Scheel C, Lutz TA, Scharrer E. Site-specific effects of ghrelin on the neuronal activity in the hypothalamic arcuate nucleus. Neurosci Lett 2003;341:151-5.
17. Jhanwar-Uniyal M, Beck B, Jhanwar YS, Burlet C, Leibowitz SF. Neuropeptide Y projection from arcuate nucleus to parvocellular division of paraventricular nucleus: Specific relation to the ingestion of carbohydrate. Brain Res 1993;631:97-106.
18. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999;20:68-100.
19. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992-5.
20. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, et al. Elevated plasma ghrelin levels in Prader-Willi syndrome. Nat Med 2002;8:643-4.
21. DelParigi A, Tschop M, Heiman ML, Salbe AD, Vozarova B, Sell SM, et al. High circulating ghrelin: A potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 2002;87:5461-4.
22. Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003;88:1594-602.
23. Hanusch-Enserer U, Brabant G, Roden M. Ghrelin concentrations in morbidly obese patients after adjustable gastric banding. N Engl J Med 2003;348:2159-60.
24. Edholm T, Levin F, Hellström PM, Schmidt PT. Ghrelin stimulates motility in the small intestine through intrinsic cholinergic neeurons. Regul Pept 2004;121:25-30.
25. Tschöp M, Viswanath D, Weyer C, Tataranni PA, Ravussin E, Meimann ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50:707-9.
26. Kirchgessner AL. Orexins in the brain-gut axis. Endocr Rev 2002;23:1-15.
27. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli R, Tanaka H, et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-85.
28. Kirchgessner AL, Liu M. Orexin synthesis and response in the gut. Neuron 1999;24:941-51.
29. Näslund E, Ehrström M, Ma J, Hellström PM, Kirchgessner AL. Localization and effects of orexin on fasting motility in the rat duodenum. Am J Physiol 2002;282: G470-9.
30. Nowak KW, Mackowiak P, Switonska MM, Fabis M, Malendowicz LK. Acute orexin effects on insulin secretion in the rat: In vivo and in vitro studies. Life Sci 2000;66:449-54.
31. Ouedrago R, Näslund E, Kirchgessner AL. Glucose regulates the release of orexin-A from the endocrine pancreas. Diabetes 2003;52:111-7.
32. Burdyga G, Lal S, Spiller D, Jiang W, Thompson D, Attwood S, et al. Localization of orexin-1 receptors to vagal afferent neurons in the rat and humans. Gastroenterology 2003;124:129-39.
33. Komaki G, Matsumoto Y, Nishikata H, Kawai K, Nozaki T, Takii M, et al. Orexin-A and leptin change inversely in fasting non-obese subjects. Eur J Endocrinol 2001;144:645-51.
34. Adam JA, Menheere PP, van Dielen FM, Soeters PB, Buurman WA, Greve JW. Decreased plasma orexin-A levels in obese individuals. Int J Obes Relat Metab Disord 2002;26:274-6.
35. Buchan AM, Polak JM, Solcia E, Capella C, Hudson D, Pearse AG. Electron immunohistochemical evidence for human intestinal I cells as the source of CCK. Gut 1978;19:403-7.
36. Kissileff HR, Pi-Sunyer X, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 1981;34:154-60.
37. Stacher G, Steinringer H, Schmierer C, Schneider C, Winklehner S. Cholecystokinin octapeptide decreases intake of solid food in man. Peptides 1982;3:133-6.
38. West DB, Fey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 1984;246:R776-87.
39. Ballinger A, McLoughlin L, Medback S, Clark M. Cholecystokinin is a satiety hormone in humans at physiological post-prandial concentrations. Clin Sci 1995;89:375-81.
40. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Satiety effects of a physiological dose of cholecystokinin in humans. Gut 1995;36:176-9.
41. Peikin SR. Role of cholecystokinin in the control of food intake. Gastrointest Endocrinol 1989;18:757-75.
42. Plata-Salaman CR. Regulation of hunger and satiety in man. Dig Dis Sci 1991;9:253-68.
43. Reidelberger RD, O'Rourke MF. Potent cholecystokinin antagonist L 364718 stimulates food intake in rats. Am J Physiol 1989;257:R1512-8.
44. Hewson G, Leighton RG, Hughes J. The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin. Br J Pharmacol 1988;93:79-84.
45. Reidelberger RD, Varga G, Solomon TE. Effects of selective cholecystokinin antagonists L364,718 and L365,260 on food intake in rats. Peptides 1991;12:1215-21.
46. Mercer JG, Lawrence CB. Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365260, for axonally-transported CCK binding sites on the rat vagus nerve. Neurosci Lett 1992;137:229-31.
47. Reubi JC, Waser B, Läderach U, Stettler C, Friess H, Halter F, et al. Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology 1997;112:1197-205.
48. Geiselman PJ. Control of food intake. Endocrinol Metab Clin North Am 1996;25:815-29.
49. French SJ, Murry B, Rumsey RD, Sepple CP, Read NW. Is cholecystokinin a satiety hormone? Correlations of plasma cholecystokinin with hunger, satiety, and gastric emptying in normal volunteers. Appetite 1991;21:95-104.
50. Emond M, Schwartz GJ, Ladenheim EE, Moran TH. Central leptin modulates behavioral and neural responsivity to CCK. Am J Physiol 1999;276:R1545-9.
51. Matson CA, Reid DF, Ritter RC. Daily CCk injection enhances reduction of body weight by chronic intracerebroventricular leptin infusion. Am J Physiol 2001;282: R1368-73.
52. Lin L, Thomas SR, Kilroy L, Schwartz GJ, York DA. Enterostatin inhibition of dietary fat intake is dependent on CCK-A receptors. Am J Physiol 2003;285:R321-8.
53. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983;302:716-8.
54. Holst JJ. Enteroglucagon. Ann Rev Physiol 1997;59:257-71.
55. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 87-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-73.
56. Näslund E, Bogefors J, Skogar S, Grybäck P, Jacobsson H, Holst JJ, et al. Glucagon-like peptide-1 slows solid gastric emptying with inhibition of insulin, C-peptide, glucagon and peptide YY release in humans. Am J Physiol 1999;277: R910-6.
57. Ørskov C. Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia 1992;35:701-11.
58. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997;273:E981-8.
59. Imeryüz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997;273:G920-7.
60. Wettergren A, Wøjdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretions in humans depends on an intact vagal innervation. Gut 1997;40:597-601.
61. Wettergren A, Wøjdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998;275: G984-92.
62. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: Effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998;43:2284-90.
63. Jin SLC, Han VKM, Simmons JG, Towle AC, Lauder JM, Lund PK. Distribution of glucagon-like peptide-1 (GLP-1), glucagon, and glicentin in the rat brain. J Comp Neurol 1988;271:519-32.
64. Shimizu I, Hirota M, Ohboshi C, Shima K. Identification and localization of the glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 1987;121:1076-82.
65. Kreymann B, Ghatei MA, Burnet P, Williams G, Kanse S, Diani AR, et al. Characterization of glucagon-like peptide-1-(7-36)amide in the hypothalamus. Brain Res 1989;502:325-31.
66. Lambert PD, Wilding PH, Ghatei MA, Bloom SR. A role for GLP-1-(7-36)NH2 in the central control of feeding behaviour. Digestion 1994;54:360-1.
67. Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Møller M, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996;271:R848-56.
68. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;385:69-72.
69. Bloom SR. Glucagon-like peptide-1 and satiety. Nature 1997;385:214.
70. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-20.
71. Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, et al. Glucagon-like peptide-1: A potent regulator of food intake in humans. Gut 1999;44:81-6.
72. Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes 2000;24:288-98.
73. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999;276:R1541-4.
74. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide-1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999;22:1137-43.
75. Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM. Glucagon-like peptide-1 (GLP-1) increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 1998;68:525-30.
76. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 in obese men. Int J Obes 1999;23:304-11.
77. Grybäck P, Hellström PM, Jacobsson H, Backman L. Gastric emptying of solids in humans: Improved evaluation by Kaplan-Meier plots, with special reference to obesity and gender. Eur J Nucl Med 1996;23:1562-7.
78. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: Cause or consequence. Gut 1996;38:916-9.
79. Näslund E, Grybäck P, Backman L, Jacobsson H, Holst JJ, Theodorsson E, et al. Small bowel gut hormones: Correlation to fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998;43:945-52.
80. Ranganath L, Norris F, Morgan L, Wright J, Marks V. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids. Clin Sci 1999;96:335-42.
81. Clément K, Dina C, Basdevant A, Chastang N, Pelloux V, Lahlou N, et al. A sib-pair analysis study of 15 candidate genes in French families with morbid obesity: Indication for linkage with islet 1 locus on chromosome 5q. Diabetes 1999;48:398-402.
82. Tsai CH, Hill M, Drucker DJ. Biological determinants of intestinotrophic properties of GLP-2. Am J Physiol 1997;272:G662-8.
83. Lovshin J, Drucker DJ. New frontiers in the biology of GLP-2. Regul Pept 2000;90:27-32.
84. Wøjdemann M, Wettergren A, Hartmann B, Holst JJ. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998;33:828-32.
85. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 2000;6:802-7.
86. Schmidt PT, Näslund E, Grybäck P, Jacobsson H, Hartmann B, Holst JJ, et al. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 2003;116:21-5.
87. Sørensen LB, Flint A, Raben A, Hartmann B, Holst JJ, Astrup A. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord 2003;27:450-6.
88. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004;145:2687-95.
89. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003;88:4696-701.
90. Morley JE, Levine AS, Grace M, Kneip J. Peptide YY (PYY), a potent orexigenic agent. Brain Res 1985;341:200-3.
91. Hagan MM. Peptide YY: A key mediator of orexigenic behavior. Peptides 2002;23:377-82.
92. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003;349:941-8.
93. Batterham RL. Gut hormone PYY3-36 physiologically inhibits food intake. Nature 2002;418:650-4.
94. Clark JT, Kalra PS, Crowley WR, Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 1984;115:427-9.
95. Stanley BG, Leibowitz SF. Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sci 1984;35:2635-42.
96. Levine AS, Morley JE. Neuropeptide Y: A potent inducer of consummatory behavior in rats. Peptides 1984;5:1025-9.
97. Poggioli R, Vergoni AV, Bertolini A. ACTH-(1-24) and alpha-MSH antagonize feeding behavior stimulated by kappa opiate agonists. Peptides 1986;7:843-8.
98. Fan W, Boston BA, Kesterson R, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997;385:165-8.
99. Schiöth HB. The physiological role of melanocortin receptors. Vitam Horm 2001;63:195-232.
100. Broberger C, Johansen J, Johansson C, Schalling M, Hökfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci USA 1998;95:15043-8.
101. Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nature 1998;1:271-2.
102. Broberger C, Landry M, Wong H, Walsh J, Hökfelt T. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in proopiomelanocortin and neuropeptide Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 1997;66:393-408.
103. Fuxe K, Tinner B, Caberlotto L, Bunnemann B, Agnati L. NPY Y1 receptor like immunoreactivity exists in a subpopulation of b-endorphin immunoreactive nerve cells in the arcuate nucleus: a double immunolabelling analysis in the rat. Neurosci Lett 1997;225:49-52.
104. Porte D Jr, Baskin DG, Schwartz MW. Leptin and insulin action in the central nervous system. Nutr Rev 2002;60: S20-9.
105. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, et al. Glucagon-like peptide-1 decreases feelings of hunger and suppresses energy intake in obese humans. Int J Obes Relat Metab Disord 1999;23:304-11.
106. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30.
107. Näslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 2004;91:1-9.
108. Taylor IL, Feldman M, Richardson CT, Walsh JH. Gastric and cephalic stimulation of human pancreatic polypeptide release. Gastroenterology 1978;75:432-7.
109. Hilsted J, Galbo H, Sonne B, Schwartz T, Fahrenkrug J, de Muckadell OB, et al. Gastroenteropancreatic hormonal changes during exercise. Am J Physiol 1980;239:G136-40.
110. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003;88:3989-92.
111. Poeschla B, Gibbs J, Simansky KJ, Greenberg D, Smith GP. Cholecystokinin-induced satiety depends on activation of 5-HT1C receptors. Am J Physiol 1993;264:R62-4.
112. Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003;52:947-52.
113. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW. High constitutive signaling of the ghrelin receptor: Identification of a potent inverse agonist. Mol Endocrinol 2003;17:2201-10.